Pharmaceutical company Pharmaxis (PXS) announced it has finalised a logistics and distribution services agreement for the supply of Bronchitol across Europe. In anticipation of a second quarter commercial launch of Bronchitol for cystic fibrosis in Europe, Pharmaxis has signed a three year agreement with Arvato Healthcare, a member of the Bertelsmann AG group of companies.
Pharmaxis Chief Executive Officer Dr Alan Robertson said, “This agreement completes the infrastructure required to make Bronchitol available throughout Europe. Arvato provides Pharmaxis with a state‐of‐the‐art healthcare distribution facility centralised in Germany from which Bronchitol is shipped directly to pharmacies and hospitals. “Launch stock of Bronchitol is in the final stages of manufacture and our Pharmaxis and Quintiles sales teams are introducing Pharmaxis to cystic fibrosis centres in the United Kingdom and Germany. The customer services and logistics are now also in place. We are looking forward to making Bronchitol available to the European cystic fibrosis patients.”
Arvato is an internationally networked outsourcing services provider employing 60,000 people in more than 30 countries. Its integrated business processes and decentralized structure provide a high standard of flexible and efficient service for customers. Pharmaxis is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes, Bronchitol for cystic fibrosis and bronchiectasis and, PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma.